Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z006278 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z002625 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
Inbound call from a HCP reporting a 12 month old was administered PROQUAD and VARIVAX. Request information on double dosing of Varicella, see request case 02839122. HCP declined to provide patient information. Lot and expiration dates were unknown fo; No additional AE; This spontaneous report was received from a nurse and refers to a 12-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Z002625, expiration date: 08-Jan-2027) and with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Z006278, expiration date: 15-Sep-2026) (overdose) for prophylaxis. The reporter requested information on double dosing of Varicella. No specific adverse effects reported (no adverse event).